A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 9, 2012, Pages 3317-3322

  Bach, Anders ^a   Clausen, Bettina H ^b   Møller, Magda ^a   Vestergaard, Bente ^a   Chi, Celestine N ^c   Round, Adam ^d   Sørensen, Pernille L ^a   Nissen, Klaus B ^a   Kastrup, Jette S ^a   Gajhede, Michael ^a   Jemth, Per ^c   Kristensen, Anders S ^a   Lundström, Patrik ^e   Lambertsen, Kate L ^b   Strømgaard, Kristian ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UPPSALA UNIVERSITY   (Sweden)

^d EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

^e LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Drug discovery; Ischemic stroke; Protein protein interactions

Indexed keywords

DIMER; NEUROPROTECTIVE AGENT; PDZ PROTEIN; PDZ1 PROTEIN; PDZ2 PROTEIN; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEINASE; TAT N DIMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; BRAIN DAMAGE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DIMERIZATION; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; MOLECULAR DYNAMICS; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BLOOD-BRAIN BARRIER; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GUANYLATE KINASE; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEARNING DISORDERS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; MOVEMENT DISORDERS; NEUROPROTECTIVE AGENTS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PDZ DOMAINS; PEPTIDES; POSTURAL BALANCE; PROTEIN CONFORMATION; SENSATION DISORDERS;

MUS;

EID: 84857753632     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1113761109     Document Type: Article

References (36)

1. Blazer LL, Neubig RR (2009) Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: Current progress and future hurdles. Neuropsychopharmacology 34:126-141.
2. Dev KK (2004) Making protein interactions druggable:Targeting PDZ domains. Nat Rev Drug Discov 3:1047-1056.
3. Christopherson KS, Hillier BJ, Lim WA, Bredt DS (1999) PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem 274:27467-27473.
4. Sattler R, et al. (1999) Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284:1845-1848. (Pubitemid 29291436)
5. Dawson VL, et al. (1991) Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 88:6368-6371. (Pubitemid 21914947)
6. Huang Z, et al. (1994) Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 265:1883-1885. (Pubitemid 24324247)
7. Aarts M, et al. (2002) Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 298:846-850. (Pubitemid 35231541)
8. Soriano FX, et al. (2008) Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J Neurosci 28:10696-10710.
9. Tymianski M (2011) Emerging mechanisms of disrupted cellular signaling in brain ischemia. Nat Neurosci 14:1369-1373.
10. Tao F, Su Q, Johns RA (2008) Cell-permeable peptide Tat-PSD-95 PDZ2 inhibits chronic inflammatory pain behaviors in mice. Mol Ther 16:1776-1782.
11. LeBlanc BW, et al. (2010) A cyclic peptide targeted against PSD-95 blocks central sensitization and attenuates thermal hyperalgesia. Neuroscience 167:490-500.
12. D'Mello R, et al. (2011) Perturbing PSD-95 interactions with NR2B-subtype receptors attenuates spinal nociceptive plasticity and neuropathic pain. Mol Ther 19:1780-1792.
13. Ittner LM, et al. (2010) Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell 142:387-397.
14. Gardoni F (2008) MAGUK proteins: New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 585:147-152.
15. Bach A, et al. (2011) Cell-permeable and plasma-stable peptidomimetic inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem 54:1333-1346.
16. Sun HS, et al. (2008) Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke 39:2544-2553.
17. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285:1569-1572. (Pubitemid 29420581)
18. Tat-NR2B9c is found under the name NA-1 at www.clinicaltrials.gov.
19. Bach A, et al. (2008) Modified peptides as potent inhibitors of the postsynaptic density- 95/N-methyl-D-aspartate receptor interaction. J Med Chem 51:6450-6459.
20. Bach A, et al. (2009) Design and synthesis of highly potent and plasma-stable dimeric inhibitors of the PSD-95-NMDA receptor interaction. Angew Chem Int Ed 48:9685-9689.
21. Chi CN, et al. (2010) Deciphering the kinetic binding mechanism of dimeric ligands using a potent plasma-stable dimeric inhibitor of postsynaptic density protein-95 as an example. J Biol Chem 285:28252-28260.
22. Wender PA, et al. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc Natl Acad Sci USA 97:13003-13008.
23. Huang X (2003) Fluorescence polarization competition assay: The range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. J Biomol Screen 8:34-38.
24. Long JF, et al. (2003) Supramodular structure and synergistic target binding of the N-terminal tandem PDZ domains of PSD-95. J Mol Biol 327:203-214.
25. Sainlos M, et al. (2011) Biomimetic divalent ligands for the acute disruption of synaptic AMPAR stabilization. Nat Chem Biol 7:81-91.
26. Paduch M, et al. (2007) Bivalent peptides as models for multimeric targets of PDZ domains. Chembiochem 8:443-452. (Pubitemid 47183663)
27. Doyle DA, et al. (1996) Crystal structures of a complexed and peptide-free membrane protein-binding domain: Molecular basis of peptide recognition by PDZ. Cell 85:1067-1076. (Pubitemid 26231173)
28. Wang W, et al. (2009) Creating conformational entropy by increasing interdomain mobility in ligand binding regulation: A revisit to N-terminal tandem PDZ domains of PSD-95. J Am Chem Soc 131:787-796.
29. Lambertsen KL, et al. (2009) Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J Neurosci 29:1319-1330.
30. Lyck L, Krøigård T, Finsen B (2007) Unbiased cell quantification reveals a continued increase in the number of neocortical neurones during early post-natal development in mice. Eur J Neurosci 26:1749-1764. (Pubitemid 47493180)
31. Pronichev I, Lenkov D (1998) Functional mapping of the motor cortex of the white mouse by a microstimulation method. Neurosci Behav Physiol 28:80-85. (Pubitemid 128697138)
32. Ginsberg MD (2008) Neuroprotection for ischemic stroke: Past, present and future. Neuropharmacology 55:363-389.
33. Hata R, et al. (2000) Dynamics of regional brain metabolism and gene expression after middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 20:306-315. (Pubitemid 30108449)
34. Hata R, et al. (2000) Evolution of brain infarction after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 20:937-946. (Pubitemid 30413677)
35. Nakagawa T, et al. (2004) Quaternary structure, protein dynamics, and synaptic function of SAP97 controlled by l27 domain interactions. Neuron 44:453-467. (Pubitemid 39423347)
36. Feng W, Zhang M (2009) Organization and dynamics of PDZ-domain-related supra-modules in the postsynaptic density. Nat Rev Neurosci 10:87-99.